This is a demo store. No orders will be fulfilled.

Mobocertinib succinate - 99%, high purity , Epidermal growth factor receptor erbB1 inhibitor, CAS No.2389149-74-8, Epidermal growth factor receptor erbB1 inhibitor

    Grade & Purity:
  • ≥99%
In stock
Item Number
M651984
Grouped product items
SKU Size
Availability
Price Qty
M651984-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$60.90
M651984-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$90.90
M651984-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$150.90
M651984-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$250.90
M651984-500mg
500mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$950.90

Basic Description

Synonyms AP32788 succinate | AP-32788 succinate | CS-0114257 | butanedioic acid;propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate | BCP33315 | MS-31177 | Propan-2-yl 2-[4-[2
Specifications & Purity ≥99%
Biochemical and Physiological Mechanisms Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR . Mobocertinib succinat
Storage Temp Store at 2-8°C,Desiccated
Shipped In
Wet ice
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type INHIBITOR
Mechanism of action Epidermal growth factor receptor erbB1 inhibitor
Product Description

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR . Mobocertinib succinate can be used in NSCLC research

In Vitro

Mobocertinib succinate (1.5 nM-10 μM; 7 days) inhibits LU0387 (NPH) cells with IC 50 of 21 nM. Mobocertinib succinate (2 h) potently inhibits EGFR with common activating mutations (HCC827 (D), HCC4011 (L)) or with a T790M mutation (H1975 (LT)) more potently than WT EGFR (A431 (WT)). Mobocertinib succinate (0.1 nM-1 μM; 6 h) inhibits pEGFR and pERK1/2 in CUTO14 (ASV) cells. Mobocertinib succinate (0.3 nM-1 μM; 6 h) inhibits EGFR and downstream signaling. Mobocertinib succinate (0.01, 0.1 and 1 μM; 6 h) inhibits HER2 signaling in H1781 (HER2 Exon 20 G776>VC ), Ba/F3 (HER2 exon 20 YVMA ) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LU0387 (NPH) cells Concentration: 1.5 nM-10 μM Incubation Time: 7 days Result: Showed good inhibition activity for LU0387 (NPH) cells with IC 50 of 21 nM. Cell Viability AssayCell Line: A431 (WT), HCC827 (D), HCC4011 (L), H1975 (LT) cells Concentration: Incubation Time: 2 h Result: Inhibited EGFR with common activating mutations of HCC827 (D), HCC4011 (L) cells and T790M mutation of H1975 (LT) with IC 50 s of 4, 1.3 and 9.8 nM respectively, which more potently than WT EGFR (A431 (WT); IC 50 of 35 nM). Western Blot AnalysisCell Line: CUTO14 (ASV) cells Concentration: 0.1 nM-1 μM Incubation Time: 6 h Result: Robustly inhibited EGFR signaling, reaching 80% and 100% inhibition of phosphorylated EGFR (pEGFR) at concentrations of 100 nM and 1 μM, respectively. Western Blot AnalysisCell Line: HCC827 (D), HCC4011 (L), H1975 (LT) cells Concentration: 0.3 nM-1 μM Incubation Time: 6 h Result: Potently inhibited EGFR and downstream signaling in HCC827 (D), HCC4011 (L) and H1975 (LT) cells. Western Blot AnalysisCell Line: H1781 (HER2 Exon 20 G776>VC ), Ba/F3 (HER2 exon 20 YVMA ) cells Concentration: 0.01, 0.1 and 1 μM Incubation Time: 6 h Result: Inhibited HER2 signaling in H1781 and Ba/F3-HER2 exon 20 YVMA mutant cells at 0.1 μM with significantly decreased phosphorylations of HER2, AKT, and ERK1/2 in a dose-dependent manner.

In Vivo

Mobocertinib succinate (3, 10, 30 mg/kg; p.o.; once daily for 20 days) significantly induces tumor growth inhibition . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Athymic Nude-Foxn1 nu mice (human NSCLC H1975 LT tumor model) . Dosage: 3, 10, 30 mg/kg Administration: Oral; once daily for 20 days. Result: Decreased the mean tumor volume by 44% and 92% when at 3 mg/kg and 10 mg/kg, respectively, relative to the tumor size of vehicle group. Induced a 76% tumor regression relative to the pretreatment tumor size at 30 mg/kg.

Form:Solid

IC50& Target:EGFR exon 20 insertion HER2 EGFR (WT)

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Benzenoids
Class Benzene and substituted derivatives
Subclass Anilides
Intermediate Tree Nodes Not available
Direct Parent 2'-Aminoanilides
Alternative Parents N-alkylindoles  Pyrimidinecarboxylic acids  Methoxyanilines  Indoles  Aminophenyl ethers  Phenoxy compounds  N-arylamides  Methoxybenzenes  Dialkylarylamines  Anisoles  Aminopyrimidines and derivatives  Alkyl aryl ethers  N-methylpyrroles  Fatty acids and conjugates  Dicarboxylic acids and derivatives  Heteroaromatic compounds  Acrylic acids and derivatives  Trialkylamines  Secondary carboxylic acid amides  Carboxylic acid esters  Amino acids and derivatives  Secondary amines  Carboxylic acids  Azacyclic compounds  Organopnictogen compounds  Organic oxides  Hydrocarbon derivatives  Carbonyl compounds  
Molecular Framework Not available
Substituents 2'-aminoanilide - N-alkylindole - Aminophenyl ether - Methoxyaniline - Pyrimidine-5-carboxylic acid or derivatives - Pyrimidine-5-carboxylic acid - Indole or derivatives - Indole - Phenoxy compound - Methoxybenzene - Aniline or substituted anilines - Dialkylarylamine - N-arylamide - Tertiary aliphatic/aromatic amine - Phenol ether - Anisole - Aminopyrimidine - Alkyl aryl ether - Fatty acid - Substituted pyrrole - Pyrimidine - N-methylpyrrole - Dicarboxylic acid or derivatives - Acrylic acid or derivatives - Heteroaromatic compound - Pyrrole - Tertiary aliphatic amine - Tertiary amine - Secondary carboxylic acid amide - Carboxylic acid ester - Carboxamide group - Amino acid or derivatives - Azacycle - Organoheterocyclic compound - Secondary amine - Ether - Carboxylic acid - Carboxylic acid derivative - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Carbonyl group - Amine - Aromatic heteropolycyclic compound
Description This compound belongs to the class of organic compounds known as 2'-aminoanilides. These are organic compounds containing an anilide moieties that carries an amino group at the 2-position of the benzene ring.
External Descriptors Not available

Names and Identifiers

IUPAC Name butanedioic acid;propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
INCHI InChI=1S/C32H39N7O4.C4H6O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26;5-3(6)1-2-4(7)8/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36);1-2H2,(H,5,6)(H,7,8)
InChIKey YXYAEUMTJQGKHS-UHFFFAOYSA-N
Smiles CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.C(CC(=O)O)C(=O)O
Isomeric SMILES CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.C(CC(=O)O)C(=O)O
Alternate CAS 2389149-74-8
PubChem CID 146026179
Molecular Weight 703.78

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Chemical and Physical Properties

Solubility DMSO : 125 mg/mL (177.61 mM; Need ultrasonic)
Molecular Weight 703.800 g/mol
XLogP3
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 13
Rotatable Bond Count 16
Exact Mass 703.333 Da
Monoisotopic Mass 703.333 Da
Topological Polar Surface Area 188.000 Ų
Heavy Atom Count 51
Formal Charge 0
Complexity 1030.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 2

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.